Your browser doesn't support javascript.
loading
Nivolumab and relatlimab for the treatment of melanoma.
Chen, Xuan-Yu; Li, Yi-Dong; Xie, Yuhao; Cao, Lu-Qi; Ashby, Charles R; Zhao, Hongbing; Chen, Zhe-Sheng.
Afiliação
  • Chen XY; Institute for Biotechnology, St. John's University, Queens, New York City, New York, USA.
  • Li YD; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York City, New York, USA.
  • Xie Y; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York City, New York, USA.
  • Cao LQ; Institute for Biotechnology, St. John's University, Queens, New York City, New York, USA.
  • Ashby CR; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York City, New York, USA.
  • Zhao H; Institute for Biotechnology, St. John's University, Queens, New York City, New York, USA.
  • Chen ZS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York City, New York, USA.
Drugs Today (Barc) ; 59(2): 91-104, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36811409
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Screening_studies Limite: Humans Idioma: En Revista: Drugs Today (Barc) Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Screening_studies Limite: Humans Idioma: En Revista: Drugs Today (Barc) Ano de publicação: 2023 Tipo de documento: Article